PCRX

MKT CAP:$1B

Pacira BioSciences, Inc.

Market Cap

$1B

Healthcare·Drug Manufacturers - Specialty & Generic·🇺🇸 United States·NASDAQ

Healthcare·Drug·🇺🇸·NASDAQ

Stock Price

$24.36-$0.10 (-0.41%)

Apr 24, 2026

Company Details

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; Z...

CEO

Frank D. Lee

IPO Date

Feb 3, 2011

Website

www.pacira.com

Key Metrics TTM

Revenue

$726M

+3.6% YoY

Net Income

$7M

EPS (Diluted)

$0.15

Free Cash Flow

$137M

Revenue / Share

$16.90

Gross Margin

77.4%

Operating Margin

2.8%

Net Margin

1.0%

FCF Margin

18.8%

P/S

1.4x

P/E

149.4x

Earnings Reports

Q1 2026

May 14, 2026

PENDING

FY 2025

Feb 26, 2026

$726M+3.6%EPS $0.16

Q4 2025

Feb 26, 2026

$197M+5.1%EPS $0.04

Q3 2025

Nov 6, 2025

$180M+6.5%EPS $0.12

Q2 2025

Aug 5, 2025

$181M+1.7%EPS -$0.11

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$158M	$122M	$17M
Q2 22	$169M	$119M	$31M
Q3 22	$167M	$117M	$21M
Q4 22	$172M	$110M	-$10M
Q1 23	$160M	$111M	-$3M
Q2 23	$169M	$121M	$40M
Q3 23	$164M	$124M	$18M
Q4 23	$181M	$134M	$33M
Q1 24	$167M	$120M	$13M
Q2 24	$178M	$134M	$28M
Q3 24	$169M	$130M	-$140M
Q4 24	$187M	$147M	$25M
Q1 25	$169M	$135M	$2M
Q2 25	$181M	$140M	$8M
Q3 25	$180M	$145M	$6M
Q4 25	$197M	$142M	$3M

Valuation

Quarter	P/S	P/E
Q1 22	5.9x	88.6x
Q2 22	4.6x	72.7x
Q3 22	3.9x	121.0x
Q4 22	2.5x	106.3x
Q1 23	2.8x	—
Q2 23	2.8x	—
Q3 23	2.1x	198.6x
Q4 23	2.4x	39.3x
Q1 24	2.0x	19.1x
Q2 24	1.9x	20.6x
Q3 24	1.0x	—
Q4 24	1.2x	—
Q1 25	1.6x	—
Q2 25	1.6x	—
Q3 25	1.6x	53.7x
Q4 25	1.6x	163.2x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	$31M	$23M
Q2 22	$30M	$18M
Q3 22	$43M	$37M
Q4 22	$42M	$37M
Q1 23	$19M	$13M
Q2 23	$43M	$40M
Q3 23	$44M	$41M
Q4 23	$48M	$46M
Q1 24	$49M	$46M
Q2 24	$53M	$52M
Q3 24	$54M	$50M
Q4 24	$33M	$31M
Q1 25	$35M	$27M
Q2 25	$12M	$9M
Q3 25	$61M	$57M
Q4 25	$44M	$43M

Capital Expenditures

Quarter	CapEx
Q1 22	$8M
Q2 22	$12M
Q3 22	$5M
Q4 22	$5M
Q1 23	$7M
Q2 23	$3M
Q3 23	$3M
Q4 23	$2M
Q1 24	$3M
Q2 24	$2M
Q3 24	$4M
Q4 24	$2M
Q1 25	$9M
Q2 25	$3M
Q3 25	$4M
Q4 25	$218.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	+32.7%	+41.2%
Q2 22	+24.9%	+37.2%
Q3 22	+31.1%	+51.8%
Q4 22	+8.0%	+17.3%
Q1 23	+1.5%	+16.2%
Q2 23	+0.0%	-6.2%
Q3 23	-2.1%	+0.0%
Q4 23	+5.4%	-18.6%
Q1 24	+4.2%	-5.8%
Q2 24	+5.0%	+15.6%
Q3 24	+2.8%	+110.7%
Q4 24	+3.3%	+9.8%
Q1 25	+1.1%	+8.5%
Q2 25	+1.7%	+15.2%
Q3 25	+6.5%	-43.8%
Q4 25	+5.1%	+19.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$11M	7.1%
Q2 22	$12M	6.8%
Q3 22	$13M	7.6%
Q4 22	$13M	7.4%
Q1 23	$12M	7.5%
Q2 23	$11M	6.5%
Q3 23	$13M	7.6%
Q4 23	$12M	6.9%
Q1 24	$13M	7.9%
Q2 24	$13M	7.0%
Q3 24	$13M	7.8%
Q4 24	$12M	6.6%
Q1 25	$15M	8.6%
Q2 25	$15M	8.5%
Q3 25	$14M	7.8%
Q4 25	$13M	6.9%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 22	$22M	$26M	$38M	—
Q2 22	$26M	$28M	$37M	—
Q3 22	$19M	$28M	$34M	—
Q4 22	$18M	$28M	$36M	—
Q1 23	$17M	$29M	$42M	—
Q2 23	$19M	$27M	$37M	—
Q3 23	$21M	$30M	$38M	—
Q4 23	$19M	$30M	$36M	—
Q1 24	$18M	$33M	$39M	—
Q2 24	$20M	$29M	$39M	—
Q3 24	$19M	$31M	$43M	—
Q4 24	$24M	$29M	$50M	—
Q1 25	$25M	$31M	$56M	—
Q2 25	$28M	$38M	$51M	—
Q3 25	$26M	$33M	$58M	—
Q4 25	$37M	—	—	$102M

Revenue Segments

Quarter

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$227M	$225M	$452M
Q2 22	$122M	$194M	$316M
Q3 22	$109M	$219M	$329M
Q4 22	$104M	$185M	$289M
Q1 23	$36M	$138M	$174M
Q2 23	$87M	$134M	$221M
Q3 23	$99M	$136M	$235M
Q4 23	$153M	$125M	$279M
Q1 24	$184M	$142M	$326M
Q2 24	$247M	$157M	$404M
Q3 24	$246M	$208M	$454M
Q4 24	$277M	$208M	$485M
Q1 25	$284M	$210M	$494M
Q2 25	$300M	$145M	$446M
Q3 25	$148M	$99M	$246M
Q4 25	$159M	$80M	$238M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	46M	+4.1%	+1.0%
Q2 22	52M	+13.0%	+15.1%
Q3 22	46M	-12.7%	+0.8%
Q4 22	46M	+0.1%	+2.9%
Q1 23	46M	+0.1%	-1.1%
Q2 23	52M	+13.3%	-0.8%
Q3 23	52M	+0.0%	+13.6%
Q4 23	52M	-0.0%	+13.5%
Q1 24	52M	+0.2%	+13.6%
Q2 24	51M	-3.2%	-2.9%
Q3 24	46M	-8.7%	-11.4%
Q4 24	49M	+6.3%	-5.8%
Q1 25	47M	-5.1%	-10.9%
Q2 25	45M	-2.3%	-10.1%
Q3 25	44M	-2.2%	-3.6%
Q4 25	43M	-3.3%	-12.3%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$226.7K	697
Q2 22	$243.1K	697
Q3 22	$240.3K	697
Q4 22	$240.5K	715
Q1 23	$224.3K	715
Q2 23	$237.0K	715
Q3 23	$229.3K	715
Q4 23	$254.6K	712
Q1 24	$234.7K	712
Q2 24	$250.0K	712
Q3 24	$236.8K	712
Q4 24	$237.0K	790
Q1 25	$213.8K	790
Q2 25	$229.2K	790
Q3 25	$227.2K	790
Q4 25	$237.5K	829

Revenue / Employee